TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06677996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varegacestat
Description: Experimental intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Description: Intervention to evaluate DDI with experimental intervention
Study: NCT06618872

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT with RO958 (experimental)
Description: the participant will have 2 PET (one with an experimental radiotracer- Tau PET), one with a standard radiotracer (amyloid-PET)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT with RO958 (experimental)
Description: the participant will have 2 PET (one with an experimental radiotracer- Tau PET), one with a standard radiotracer (amyloid-PET)
Study: NCT06151730

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05940272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hematolo-GIST Training
Description: Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants Appointment
Description: Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
Study: NCT06625411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRDN-003
Description: VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRDN-003
Description: VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
Study: NCT06624748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotional and physical support to the pregnant woman provided by attendant
Description: The companion will provide emotional and physical support to the pregnant woman (such as massage, supporting the pregnant woman while moving, taking a warm shower, etc.), and all interventions made by the companion and their duration will be recorded by the researcher in the 'Birth Process Support Form'. When the cervical dilatation is 8 cm, the Birth Comfort Scale will be applied to the pregnant woman, and two hours after the birth, the Birth Satisfaction Scale and the Postpartum Comfort Scale will be applied. Information about the birth process will be recorded in the Birth Information Form. In addition, semi-structured questions in the 'Companion Interview Form' will be asked to the companions selected for qualitative interviews and voice recording will be recorded.
Study: NCT06625424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short Sprint Interval Training with passive recovery
Description: Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which Subject will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc. Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Sprint Interval Training with Active Recovery
Description: Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which the Subjects will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc.~Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks.
Study: NCT06625398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRDN-003
Description: VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRDN-003
Description: VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
Study: NCT06690112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Drainage tube removal)
Description: During gastrectomy, a drainage tube is placed within the abdominal cavity. In Arm I (the intervention group), the drainage tube will be removed at the bedside. This procedure is a simple intervention that does not require local anesthesia and involves the removal of the drainage tube by cutting the nylon suture.
Study: NCT05823727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SOLUGEL
Description: Bovine collagen peptide supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT05068869

Intervention type: OTHER
Group type: OTHER
Intervention: Dignio Digital Remote Care intervention group
Description: The intervention consists of Dignio Prevent (for healthcare professionals) and MyDignio (for patients). The system is CE marked and the system satisfies all regulatory requirements for privacy and information security. Various components can be added for an individualized follow-up of the patients.~Elements of the digital outpatient service in Dignio include patient reported outcomes and other questionnaires, tasks, objective measures, reminders and information, in addition to a chat function for asynchronous contact with healthcare personnel and video consultations for real-time consultations.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control group
Description: Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
Study: NCT06682442

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiographic Imaging
Description: Undergo imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiographic Imaging
Description: Undergo imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Blood samples will be collected

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Blood samples will be collected
Study: NCT06686394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: Patritumab deruxtecan administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: Patritumab deruxtecan administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: Patritumab deruxtecan administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Biosimilar
Description: Trastuzumab biosimilar administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Biosimilar
Description: Trastuzumab biosimilar administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Biosimilar
Description: Trastuzumab biosimilar administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib administered as oral tablets
Study: NCT06424860

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: For 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 12 months

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fish Oil and Metformin
Description: 12 months
Study: NCT06693765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144
Description: AZD4144 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144
Description: AZD4144 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144
Description: AZD4144 will be administered orally.
Study: NCT06719180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Injection into the vaginal cuff will occur before vaginal cuff closure with stratafix suture. There will be four points of injection 1cm from the edges of the vaginal cuff with a sterilized needle to a depth of 3-4cm. 5cc of bupivacaine with epinephrine or 5cc of normal saline will be injected into each area

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: A saline placebo
Study: NCT06688344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fESWT
Description: fESWT will be applied for 1 session between weeks 4-9. The device will be set to low intensity at 0.20 mJ/mm2 - 4 Hz, 500 pulses will be applied from the tibiofemoral interval to the center of the tibiofemoral joint, and 1000 pulses will be applied to the soft tissues around the patella.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Participants will be included in the traditional physiotherapy program for the first 9 weeks, and exercise progression will be provided in the form of weekly checks in the 10-12 week period. Between the 12-24th weeks, the exercise program will continue with face-to-face follow-up twice a month.~The traditional physiotherapy program to be applied in the first 9-week period will be as follows :~Week 1 Weight Transfer as Tolerable, NMES, Elevation, Cold Application, Ankle Pumping Exercises, Heel Slide Exercises, Isometric Quadriceps Exercises, Straight Leg Raise Exercises, Extension Brace~Week 2-3 Weight Transfer, Gait Training, NMES, Heel Slide Exercises, Straight Leg Raise, Quadriceps and Adductor Isometric Exercises, Extension Brace, Bicycle, Hip Abduction-Adduction Exercises~Week 4-8. week Mini Squat, Leg Press, Soft Ground Walking, Neuromuscular Training on Balance Board, Functional Strengthening with Elastic Band, Stair Climbing Up and Down

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Participants will be included in the traditional physiotherapy program for the first 9 weeks, and exercise progression will be provided in the form of weekly checks in the 10-12 week period. Between the 12-24th weeks, the exercise program will continue with face-to-face follow-up twice a month.~The traditional physiotherapy program to be applied in the first 9-week period will be as follows :~Week 1 Weight Transfer as Tolerable, NMES, Elevation, Cold Application, Ankle Pumping Exercises, Heel Slide Exercises, Isometric Quadriceps Exercises, Straight Leg Raise Exercises, Extension Brace~Week 2-3 Weight Transfer, Gait Training, NMES, Heel Slide Exercises, Straight Leg Raise, Quadriceps and Adductor Isometric Exercises, Extension Brace, Bicycle, Hip Abduction-Adduction Exercises~Week 4-8. week Mini Squat, Leg Press, Soft Ground Walking, Neuromuscular Training on Balance Board, Functional Strengthening with Elastic Band, Stair Climbing Up and Down

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: shamfESWT
Description: Participants in the control group will receive sham fESWT once a week in weeks 4-9. Participants will be prepared in the same way as the fESWT procedure, but the application will be done with a sham device.
Study: NCT06717438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: Capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPN14770
Description: Capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study: NCT06719219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTB-SA7
Description: LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTB-SA7
Description: LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTB-SA7
Description: LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTB-SA7
Description: LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTB-SA7
Description: LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTB-SA7
Description: LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Phosphate with Sodium Chloride
Study: NCT06715943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsule
Description: HRS-5965 capsule treatment
Study: NCT06750146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System
Description: The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.
Study: NCT06752850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa
Description: 50 IU/kg once weekly, Intravenous injection
Study: NCT06751784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fampridine SR
Description: Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active substance
Study: NCT06762834

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ginger tea
Description: determine the optimal dosage of ginger tea that produces significant blood pressure reduction without adverse effects.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: self administred Ginger tea
Description: To identify consumption and its correlation with blood pressure outcomes using a self- reported diary and periodic clinical assessments.
Study: NCT06763341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCNA Inhibitor AOH1996
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCNA Inhibitor AOH1996
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCNA Inhibitor AOH1996
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06763575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Glove-Compression Therapy
Description: In the intervention group, patients wore double-layered surgical gloves, one size smaller than measured, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-compressive plastic gloves
Description: In the control group, patients wore non-compressive plastic gloves, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.
Study: NCT06763406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Due to the limited research on exercise approaches for pectus excavatum, further investigation in this field is needed. This study aims to explore the impact of Schroth-based exercise therapy on adolescents with pectus excavatum.
Study: NCT06763159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20124 (Phase Ia：Dose escalation )
Description: Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20124 (Phase Ib: Dose expansion)
Description: Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Study: NCT06764732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bioactive glass
Description: supplied as resorbable form, (400-800um) particle siz

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bioactive glass
Description: supplied as resorbable form, (400-800um) particle siz

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: bioactive glass graft and PBM irradiation
Description: The used laser parameters were set as: wavelength, 980 nm; power, 0.55 W; energy, 36 J; power density, 0.76 W cm2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Platelet rich fibrin
Description: 10 ml of blood was withdrawn from the patient and immediately centrifuged for 10 minutes at 3000 revolutions/min and the layer of fibrin clot was obtained

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: 10 ml of blood was withdrawn from the patient and immediately centrifuged for 10 minutes at 3000 revolutions/min and the layer of fibrin clot was obtained

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: 10 ml of blood was withdrawn from the patient and immediately centrifuged for 10 minutes at 3000 revolutions/min and the layer of fibrin clot was obtained
Study: NCT06763107

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Athletic Shoulder (ASH) and Inverse Athletic Shoulder (IASH) Tests
Description: Participants perform the Athletic Shoulder (ASH) test and Inverse Athletic Shoulder (IASH) test to measure maximal isometric shoulder strength in three positions (180º, 135º, 90º) during two separate sessions. Data is used to assess test reliability and validity for high-performance swimmers.
Study: NCT06764771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986488
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986488
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986488
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986488
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986488
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986488
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986488
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986488
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days